SCHEMBL2006115

SCHEMBL2006115

CC(C#N)OP(N(C)C)N(C)C

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1060663 0.78 TSHR (0.30) TSHR
SCHEMBL1061644 0.76
SCHEMBL2006417 0.75
SCHEMBL2384813 0.73 TSHR (0.39) TSHR
SCHEMBL9436377 0.69 TSHR (0.35) TSHR
SCHEMBL78637 0.69 TSHR (0.35) TSHR
SCHEMBL10632508 0.69
SCHEMBL2384817 0.69
SCHEMBL887785 0.68 TSHR (0.30) TSHR
SCHEMBL6325646 0.67 TSHR (0.33) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7247720-B2 Phosphitylation process AVECIA BIOTECHNOLOGY INC. (US) 2007-07-24 US claimed
EP-1554300-B1 PHOSPHITYLATION PROCESS AVECIA BIOTECHNOLOGY INC (US) 2007-05-23 EP claimed
US-20060069247-A1 Phosphitylation process AVECIA BIOTECHNOLOGY INC. (US) 2006-03-30 US claimed
EP-1590361-B1 PROCESS FOR PURIFYING OLIGONUCLEOTIDE SYNTHONS NITTO DENKO AVECIA INC (US) 2015-03-04 EP disclosed
US-7960542-B2 Process for purifying oligonucleotide synthons AVECIA BIOTECHNOLOGY, INC. (US) 2011-06-14 US disclosed
EP-1575965-B1 PROCESS FOR THE PREPARATION OF PHOSPHITYLATION AGENTS AVECIA BIOTECHNOLOGY INC (US) 2011-06-01 EP disclosed
US-7560555-B2 Process for the preparation of phosphitylation agents AVECIA BIOTECHNOLOGY INC. (US) 2009-07-14 US disclosed
US-7247720-B2 Phosphitylation process AVECIA BIOTECHNOLOGY INC. (US) 2007-07-24 US disclosed
EP-1554300-B1 PHOSPHITYLATION PROCESS AVECIA BIOTECHNOLOGY INC (US) 2007-05-23 EP disclosed
US-20060173187-A1 Process for the preparation of phosphitylation agents NITTO DENKO AVECIA, INC. 2006-08-03 US disclosed
US-20060135760-A1 Process for purifying oligonucleotide synthons NITTO DENKO AVECIA, INC. 2006-06-22 US disclosed
US-20060069247-A1 Phosphitylation process AVECIA BIOTECHNOLOGY INC. (US) 2006-03-30 US disclosed
EP-1575965-A1 PROCESS FOR THE PREPARATION OF PHOSPHITYLATION AGENTS Avecia Limited (GB) 2005-09-21 EP disclosed
EP-1554300-A1 PHOSPHITYLATION PROCESS Avecia Biotechnology, Inc. (US) 2005-07-20 EP disclosed
WO-2004055030-A1 PROCESS FOR THE PREPARATION OF PHOSPHITYLATION AGENTS AVECIA LIMITED (GB) 2004-07-01 WO disclosed
WO-2004035599-A1 PHOSPHITYLATION PROCESS AVECIA BIOTECHNOLOGY INC. (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135760-A1 Process for purifying oligonucleotide synthons NUDT1, POLN, POLRMT TSHR 1922/4885
US-20060069247-A1 Phosphitylation process PHOSPHO1, MTAP, PNP TSHR 1849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.